Weissmann, Thomas http://orcid.org/0000-0002-1443-5422
Rückert, Michael http://orcid.org/0000-0002-9605-4841
Putz, Florian http://orcid.org/0000-0003-3966-2872
Donaubauer, Anna-Jasmina http://orcid.org/0000-0002-1655-373X
Hecht, Markus http://orcid.org/0000-0003-2082-216X
Schnellhardt, Sören http://orcid.org/0000-0003-0418-4401
Schubert, Philipp
Roesch, Johannes
Höfler, Daniel
Ott, Oliver J. http://orcid.org/0000-0001-5806-6158
Haderlein, Marlen
Lettmaier, Sebastian
Fietkau, Rainer
Frey, Benjamin http://orcid.org/0000-0001-6743-3351
Gaipl, Udo S. http://orcid.org/0000-0001-6375-5476
Deloch, Lisa http://orcid.org/0000-0002-5577-2302
Funding for this research was provided by:
BMBF (02NUK073)
BMBF (02NUK017G)
BMBF (02NUK050E)
Bayerische Forschungsstiftung (AZ-1495-20)
Universitätsklinikum Erlangen
Article History
Received: 17 August 2022
Accepted: 25 November 2022
First Online: 5 January 2023
Conflict of interest
: M. Hecht: conflict of interest with Merck Serono (advisory role, speakers’ bureau, honoraria, travel expenses, research funding); MSD (advisory role, speakers’ bureau, honoraria, travel expenses, research funding); AstraZeneca (research funding); Novartis (research funding); BMS (advisory role, honoraria, speakers’ bureau); and Teva (travel expenses). R. Fietkau: conflict of interest Astra-Zeneca and MSD as well as honoraria from Merck Serono, Astra-Zeneca, MSD, Novocure, and research funding from Fresenius Nutrition, Merck Oncology, MSD, Astra-Zeneca, Novocure, and Siemens AG. F. Putz reports grants and speaker fees from Siemens Healthcare GmbH and Varian not related to the present work. T. Weissmann, M. Rückert, A.-J. Donaubauer, S. Schnellhardt, P. Schubert, J. Roesch, D. Höfler, O.J. Ott, M. Haderlein, S. Lettmaier, B. Frey, U.S. Gaipl, and L. Deloch declare that they have no competing interests.